Canakinumab

Canakinumab
	Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry 5bvp
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-1β
Clinical data
Trade names	Ilaris
Other names	ACZ885, ACZ-885
AHFS/Drugs.com	Monograph
MedlinePlus	a622024
License data	US DailyMed: Canakinumab;
Pregnancy; category	AU: B3;
Routes of; administration	Intravenous, subcutaneous
ATC code	L04AC08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	914613-48-2 ;
DrugBank	DB06168 ;
ChemSpider	none;
UNII	37CQ2C7X93;
KEGG	D09315;
ChEMBL	ChEMBL1201834 ;
Chemical and physical data
Formula	C6452H9958N1722O2010S42
Molar mass	145157.20 g·mol−1
	(what is this?) (verify)

Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.